<PAGE>


Exhibit 99.3

SUCCESSFUL FATIGUE LIFE TEST CONFIRMS DURABILITY OF MIV THERAPEUTICS'
HYDROXYAPATITE STENT COATING

Tuesday January 20, 9:30 am ET

VANCOUVER, Jan. 20 /PRNewswire-FirstCall/ - MIV Therapeutics Inc. (MIVT:OTCBB;
MIV:BSE; MIV1:Frankfurt) is pleased to announce that it has successfully
completed an essential fatigue life test of its proprietary hydroxyapatite (HAp)
stent coating. The test titled "In-Vitro 40 Million Cycle Accelerated Fatigue
Test for Stents with MIV Therapeutics' HAp Coating" was conducted to evaluate
the mechanical integrity and bonding properties of MIVT's ultra-thin
biocompatible coating.

This test was independently conducted by Minnesota based EnduraTEC Testing
Services Inc. who specialize in fatigue life testing of intravascular stents.
The test was performed on 32 HAp coated stents, which were deployed into
artificial arteries in the EnduraTEC Model 9010-8 stent/graft fatigue tester
(SGT). This test simulates the radial strain produced by heartbeats in a
coronary artery. Test parameters included radial strain, cycle count,
temperature, pressure gradient, and stent migration. Additionally, microporous
filters were installed in the saline circuit of the testing device to daily
monitor for any loose particles of hydroxyapatite that might have separated from
the coated stents. These filters were then thoroughly evaluated at The
University of British Columbia (UBC) where Scanning Electron Microscopy (SEM)
was used for electronic magnification of samples and Energy Dispersed X-ray
Spectroscopy (EDX) technology was used for microanalysis of the microporous
membranes.

EnduraTEC summarized, "Sixteen stainless steel and sixteen cobalt- chromium
stents, all coated with MIVT proprietary HAp coating, were subjected to 40
million cardiovascular cycles representing over one year of implantation life at
an average of 72 heartbeats per minute. There were zero failures of the stent
structure detected by EnduraTEC during visual inspection which included
evaluation of the general condition of both the tested stainless steel and
cobalt-chromium stents coated with MIV Therapeutics' proprietary hydroxyapatite
(HAp) coating."

Dr. Tom Troczynski, MIVT's Vice President of Coatings commented, "EnduraTEC's
test results confirm our preliminary assessment of the bonding properties of our
HAp coating. Subsequent analysis of the filters at UBC showed no evidence of
hydroxyapatite particles. These results are extremely rewarding and validate our
earlier expectations regarding the durability of our ultra-thin coating."

MIVT President and CEO, Alan Lindsay adds, "The critical path of our R&D program
has passed another essential milestone. Our HAp coating had previously
successfully completed a critical thrombogenicity animal trial where it was
exposed to blood-flow and showed no signs of toxicity or thrombosis (blood-
clotting). This test with EnduraTEC now shows that the coating is able to
withstand the rigorous demands of the circulatory system over time. This fatigue
life test is a cornerstone of a comprehensive range of mechanical and animal
testing required for the successful commercialization of our proprietary HAp
coating technology."

Mr. Lindsay continues, "The stent industry, due to the demand for coatings and
therapeutics, is expected to generate $6 Billion USD annually by 2006. We
believe there is an opportunity for MIVT to make a meaningful impact by
introducing a next-generation coating technology for stents that will provide
significant benefits in treatment of cardiovascular disease. Our unique
biocompatible HAp Stent Coating is made from a material that is natural to the
human body and has been developed to offer an attractive alternative to the
polymer coatings currently offered by the industry. Our objective is to provide
mankind with a cost-effective biocompatible stent-coating solution, as well as a
coating of choice for stent drug-delivery systems that will provide solutions
for blocked arteries that lead to cardiovascular disease."

<PAGE>

About EnduraTEC Testing Services, Inc.

EnduraTEC Testing Services, Inc. is a privately held company located in
Minnetonka, Minnesota, USA, with over ten years experience providing testing
services in intravascular and orthopaedic medical device evaluation. Leading
biomedical companies have used EnduraTEC Testing Services to perform accelerated
life testing under FDA and ASTM guidelines. By providing advanced testing
services for stents since 1995, EnduraTEC Testing Services has established
itself as a leader in intravascular testing. Visit www.enduratec.com for more
information.


About MIV Therapeutics


MIV Therapeutics is developing a "next generation" line of advanced
biocompatible stent coatings. The HAp coating technology has successfully passed
animal trials focused on thrombogenicity (blood-clotting). MIVT's ultra- thin
coating has been designed to inhibit inflammatory response without drugs.
Additionally, a Collaborative Research Agreement between MIVT and the University
of British Columbia has been rewarded a research and development grant from the
Natural Sciences and Engineering Research Council of Canada (NSERC) for the
development of HAp as a drug eluting coating. MIVT's manufacturing facility
maintains a comprehensive QA (Quality Assurance) system that meets the
guidelines applicable to CE Mark, FDA and GMP requirements and is capable of
private label manufacturing and out-sourcing.

         Please visit www.mivtherapeutics.com for more information.

    Product inquiries and business opportunities:
    Arc Rajtar
    arajtar@mivi.ca
    ---------------
    (604) 301-9545 ext 22

Except for the historical information contained herein, the matters discussed in
this press release are forward-looking statements. Such statements are indicated
by words or phrases such as "successfully", "passed", "demanding",
"significant", "indicated", "expectations", "critical", "milestone",
"commercialization", "extremely", "believe" and "completed". These statements
are made under "Safe Harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those described in
forward-looking statements and are subject to risks and uncertainties. See the
Company's filings with the Securities and Exchange Commission including, without
limitation, the Company's recent Form 10-K and Form 10-Qs, which identify
specific factors that may cause actual results or events to differ materially
from those described in the forward-looking statements.